Atzin MJA, Saldaña VAK, Bernal D, Vázquez ME, Serrato PA, Gorocica RP

Idioma: Español
Referencias bibliográficas: 36
Paginas: 295-303
Archivo PDF: 137.12 Kb.

RESUMEN

MUC1 es una O-glicoproteína expresada en la parte apical de epitelios normales pero frecuentemente cambia su distribución, estructura e inmunogenicidad en células tumorales de adenocarcinomas y estos cambios se asocian al comportamiento tumoral. La O-glicosilación de la MUC1 en las células neoplásicas es truncada, dando lugar al antígeno Tn (MUC1-Tn) o al antígeno T (MUC1-T). Tanto MUC1-Tn como MUC1-T pueden ser inmunogénicos y posiblemente rompan la tolerancia hacia las células neoplásicas para favorecer el infiltrado inflamatorio en la zona del tumor. El objetivo de este trabajo es identificar las características sacarídicas de MUC1 hipoglicosilada en pacientes con adenocarcinoma pulmonar. Este estudio comprendió 5 pacientes con diagnóstico clínico e histopatológico de adenocarcinoma pulmonar en estadio clínico IV. Por medio de inmunohistoquímica se determinó la presencia de MUC1-Tn y MUC1-T utilizando el anticuerpo MUC1 clona DF3 dirigido a la forma no glicosilada o hipoglicosilada de MUC1. Además se usaron las lectinas Vicia villosa para identificar el antígeno Tn y Arachis hypogea para identificar al antígeno T. La evaluación fue por microscopia de luz y análisis digital de imágenes. Los resultados mostraron aumento en la expresión de MUC1 hipoglicosilada en membrana y citoplasma de células del tumor primario que correlacionó positivamente con la expresión del antígeno Tn, pero no con el antígeno T. Con respecto a las metástasis, se encontró correlación positiva en la expresión de MUC1 con los antígenos Tn y T, excepto en encéfalo, corazón y diafragma, lo que sugiere que el análisis de la expresión de MUC1 en adenocarcinoma pulmonar puede ser un indicador importante para el pronóstico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Gurrola-Díaz CM, González-Santiago AE, Troyo-Sanromán R, Mendoza-Topete LA. Lung cancer histological types and diagnostic methods in a tertiary care facility. Gac Med Mex 2009;145:97-101.

2. Brambilla E. Classification of broncho-pulmonary cancers (WHO 1999). Rev Mal Respir 2002;19:455-466.

3. Franklin WA. Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. Chest 2000;117(4 suppl 1):80-89.

4. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-278.

5. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001;6:339-353.

6. Liu B, Lague JR, Nunes DP, et ál. Expression of membrane-associated mucin MUC1 and MUC4 in major human salivary glands. J Histochem Cytochem 2002;50:811-820.

7. Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992;17:359-363.

8. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002;99:10231-10233.

9. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.

10. Mouritsen S, Meldal M, Christiansen-Brams I, Elsner H, Werdelin O. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex class II molecules and peptide immunogenicity. Eur J Immunol 1994;24:1066-1072.

11. Laidler P, Lityn´ ska A. Tumor cell N-glycans in metastasis. Acta Biochim Pol 1997;44:343-357.

12. Couldrey C, Green JE. Metastases: the glycan connection. Breast Cancer Res 2000;2:321-323.

13. Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis 2002;19:339-345.

14. Bagriacik EU, Miller KS. Cell surface sialic acid and the regulation of immune cell interactions: the neuraminidase effect reconsidered. Glycobiology 1999;9:267-275.

15. Xu Y, Sette A, Sidney J, Gendler SJ, Franco A. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol 2005;83: 440-448.

16. Stepensky D, Tzehoval E, Vadai E, Eisenbach L. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006;143: 139-149.

17. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995;57:607-634.

18. Leroy X, Buisine MP, Leteurtre E, et ál. MUC1 (EMA): a key molecule of carcinogenesis? Ann Pathol 2006;26:257-266.

19. Copin MC, Devisme L, Buisine MP, et ál. From normal respiratory mucosa to epidermoid carcinoma: expression of human mucin genes. Int J Cancer 2000;86: 162-168.

20. Ho SB, Kim YS. Carbohydrate antigens on cancer-associated mucin-like molecules. Semin Cancer Biol 1991;2:389-400.

21. Quinlin IS, Burnside JS, Dombrowski KE, Phillips CA, Dolby N, Wright SE. Context of MUC1 epitope: immunogenicity. Oncol Rep 2007;17:453-456.

22. Reis CA, David L, Seixas M, Burchell J, Sobrinho-Simões M. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 1998;79:402-410.

23. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997;47:813-830.

24. Fernandez-Rodriguez J, Dwir O, Alon R, Hansson GC. Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions. Glycoconj J 2001;18:925-930.

25. Sheehan DC, Hrapchack BB. Theory and practice of histotechnology. 2nd ed. St Louis: Mosby; 1980.p. 196-197.

26. Loughlin PM, Cooke TG, George WD, Gray AJ, Stott DI, Going JJ. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method. J Immunol Methods 2007;321:32-40.

27. Tamada S, Goto M, Nomoto M, et ál. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int 2002;52:713-723.

28. Baldus SE, Wienand JR, Werner JP, et ál. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int J Oncol 2005;27:1289-1297.

29. Irimura T, Denda K, Iida S, Takeuchi H, Kato K. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity. J Biochem 1999;126: 975-985.

30. Chandrasekaran EV, Xue J, Neelamegham S, Matta KL. The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans. Carbohydr Res 2006;341:983-994.

31. Wu AM, Wu JH, Shen F. Interaction of a novel Tn (GalNAc alpha 1—>Ser/Thr) glycoprotein with Gal, GalNAc and GlcNAc specific lectins. Biochem Biophys Res Commun 1994;198:251-256.

32. Peracaula R, Barrabés S, Sarrats A, Rudd PM, de Llorens R. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers 2008;25:207-218.

33. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1999;1473:67-95.

34. Amaya S, Sasaki M, Watanabe Y, et ál. Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis. Histopathology 2001;38:550-560.

35. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91: 1973-1982.

36. Croce MV, Isla-Larrain M, Tur R, Rabassa ME, Segal-Eiras A. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients. Clin Exp Metastasis 2004;21:139-147.